The National Institute for Health and Care Excellence

Hundreds to benefit from new treatment option for mantle cell lymphoma and chronic lymphocytic leukaemia

Mantle cell lymphoma. MCL is a rare and aggressive type of non-Hodgkin lymphoma. It is considered incurable with current treatments and often comes back. Many people are diagnosed ...
The National Institute for Health and Care Excellence

Harnessing the potential of AI to bring real benefits for patients

Artificial intelligence has huge potential to improve health and care, but its use must be safe, effective and fair. In this ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
The National Institute for Health and Care Excellence

New lung preservation machine could make hundreds of unused donor lungs available for transplant

With only 1 in 5 donated lungs currently considered suitable for use, the introduction of the XVIVO Perfusion System for a 4-year period while evidence is generated, could benefit hundreds of NHS ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
National Institute for Health and Care Excellence

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

There is a simple discount patient access scheme for vorasidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over ...
National Institute for Health and Care Excellence

Patients to get new medicines 3 to 6 months faster

An aligned pathway between the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE, along with an improved advice service, will help bring medicines to patients faster and give ...
National Institute for Health and Care Excellence

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Rare diseases

This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement. Rare diseases are ...
National Institute for Health and Care Excellence

Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)

NICE is unable to make a recommendation on clascoterone (Winlevi) for treating acne vulgaris in people 12 years and over. This is because the company did not provide an evidence submission.
National Institute for Health and Care Excellence

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...